Immunosuppression in liver transplantation beyond calcineurin inhibitors

John J. Fung, Dympna Kelly, Zakiyah Kadry, Kusum Patel-Tom, Bijan Eghtesad

Research output: Contribution to journalReview article

68 Citations (Scopus)

Abstract

Although calcineurin inhibitors (CNIs) remain the mainstay of immunosuppression in liver transplantation (LTX), their long-term toxicity significantly contributes to morbidity and mortality. The elucidation of mechanisms of alloimmunity and leukocyte migration have provided novel targets for immunosuppression development. The toxicities of these agents differ from that of the CNI and act additively or synergistically. CNI avoidance protocols in LTX have not been achieved routinely; however, pilot trials have begun to delineate the limitations and promises of such approaches. CNI-sparing protocols appear to be much more promising in balancing the early need for minimizing rejection while tapering doses and minimizing long-term toxicity.

Original languageEnglish (US)
Pages (from-to)267-280
Number of pages14
JournalLiver Transplantation
Volume11
Issue number3
DOIs
StatePublished - Mar 1 2005

Fingerprint

Liver Transplantation
Immunosuppression
Leukocytes
Morbidity
Mortality
Calcineurin Inhibitors

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hepatology
  • Transplantation

Cite this

Fung, John J. ; Kelly, Dympna ; Kadry, Zakiyah ; Patel-Tom, Kusum ; Eghtesad, Bijan. / Immunosuppression in liver transplantation beyond calcineurin inhibitors. In: Liver Transplantation. 2005 ; Vol. 11, No. 3. pp. 267-280.
@article{5648e8f66df1426b9638ee09875c42ec,
title = "Immunosuppression in liver transplantation beyond calcineurin inhibitors",
abstract = "Although calcineurin inhibitors (CNIs) remain the mainstay of immunosuppression in liver transplantation (LTX), their long-term toxicity significantly contributes to morbidity and mortality. The elucidation of mechanisms of alloimmunity and leukocyte migration have provided novel targets for immunosuppression development. The toxicities of these agents differ from that of the CNI and act additively or synergistically. CNI avoidance protocols in LTX have not been achieved routinely; however, pilot trials have begun to delineate the limitations and promises of such approaches. CNI-sparing protocols appear to be much more promising in balancing the early need for minimizing rejection while tapering doses and minimizing long-term toxicity.",
author = "Fung, {John J.} and Dympna Kelly and Zakiyah Kadry and Kusum Patel-Tom and Bijan Eghtesad",
year = "2005",
month = "3",
day = "1",
doi = "10.1002/lt.20373",
language = "English (US)",
volume = "11",
pages = "267--280",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

Immunosuppression in liver transplantation beyond calcineurin inhibitors. / Fung, John J.; Kelly, Dympna; Kadry, Zakiyah; Patel-Tom, Kusum; Eghtesad, Bijan.

In: Liver Transplantation, Vol. 11, No. 3, 01.03.2005, p. 267-280.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Immunosuppression in liver transplantation beyond calcineurin inhibitors

AU - Fung, John J.

AU - Kelly, Dympna

AU - Kadry, Zakiyah

AU - Patel-Tom, Kusum

AU - Eghtesad, Bijan

PY - 2005/3/1

Y1 - 2005/3/1

N2 - Although calcineurin inhibitors (CNIs) remain the mainstay of immunosuppression in liver transplantation (LTX), their long-term toxicity significantly contributes to morbidity and mortality. The elucidation of mechanisms of alloimmunity and leukocyte migration have provided novel targets for immunosuppression development. The toxicities of these agents differ from that of the CNI and act additively or synergistically. CNI avoidance protocols in LTX have not been achieved routinely; however, pilot trials have begun to delineate the limitations and promises of such approaches. CNI-sparing protocols appear to be much more promising in balancing the early need for minimizing rejection while tapering doses and minimizing long-term toxicity.

AB - Although calcineurin inhibitors (CNIs) remain the mainstay of immunosuppression in liver transplantation (LTX), their long-term toxicity significantly contributes to morbidity and mortality. The elucidation of mechanisms of alloimmunity and leukocyte migration have provided novel targets for immunosuppression development. The toxicities of these agents differ from that of the CNI and act additively or synergistically. CNI avoidance protocols in LTX have not been achieved routinely; however, pilot trials have begun to delineate the limitations and promises of such approaches. CNI-sparing protocols appear to be much more promising in balancing the early need for minimizing rejection while tapering doses and minimizing long-term toxicity.

UR - http://www.scopus.com/inward/record.url?scp=16244365873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16244365873&partnerID=8YFLogxK

U2 - 10.1002/lt.20373

DO - 10.1002/lt.20373

M3 - Review article

C2 - 15719409

AN - SCOPUS:16244365873

VL - 11

SP - 267

EP - 280

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 3

ER -